SEATTLE GENETICS INC /WA | 2013 | FY | 3


The following table summarizes research and development expenses incurred by the Company and funding provided to Agensys under the collaboration to achieve equal cost sharing.

 

     Years ended December 31,  
     2013      2012      2011  

Research and development expense using contractual rates

   $ 2,574       $ 4,885       $ 6,404   

Co-development funding due to Agensys

     8,096         5,484         6,844   
  

 

 

    

 

 

    

 

 

 

Total

   $ 10,670       $ 10,369       $ 13,248   
  

 

 

    

 

 

    

 

 

 

us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock